Complete dosing reference for bupivacaine — adult and pediatric max doses, age-based tiers, cardiotoxicity warnings, IVRA contraindication, available concentrations, and pharmacokinetics.
Clinical Disclaimer: This reference is for educational purposes only and does not replace clinical judgment. Always verify doses against institutional protocols, patient weight, comorbidities, and total local anesthetic load (fractional toxicity) before administration. Not a substitute for professional medical advice.
Adult Dosing
Formulation
Max Dose (mg/kg)
Absolute Max (mg)
Bupivacaine (plain)
2.5 mg/kg
175 mg
Bupivacaine + Epinephrine
3 mg/kg
225 mg
Source: Adult values follow the FDA Marcaine label — 175 mg without epinephrine, 225 mg with epinephrine, and no more than 400 mg in any 24-hour period. The adult value is a single label number and is used directly as the fractional toxicity denominator.
Pediatric Age-Based Dosing Tiers
Pediatric doses are derived from adult max doses using age-based percentage reductions that account for immature hepatic metabolism (CYP3A4 maturation at 9–12 months).
Age Tier
% of Adult Dose
Without Epi (mg/kg)
With Epi (mg/kg)
Neonate (<1 month)
50%
1–1.25 mg/kg
1.5 mg/kg
Young Infant (1–<6 months)
70%
1.4–1.75 mg/kg
2.1 mg/kg
Older Infant (6–<12 months)
87.5%
1.75–2.19 mg/kg
2.625 mg/kg
Child (1–7 years)
100%
2–2.5 mg/kg
3 mg/kg
Adolescent (8–17 years)
100%
2–2.5 mg/kg
3 mg/kg
Infusion limits: Bupivacaine continuous infusion rates use a 4-tier age stratification: neonatal, <4 months, 4 months–1 year, and >1 year. Always consult institutional protocols for infusion dosing.
Cardiotoxicity Warning
Cardiotoxicity Rank: 5/5 — MOST CARDIOTOXIC among common local anesthetics.
Bupivacaine has a low CC:CNS ratio (cardiac collapse to CNS toxicity ratio), meaning cardiac arrest can occur with minimal preceding neurological warning signs. It binds sodium channels with high affinity and slow dissociation ("fast-in, slow-out"), making resuscitation from bupivacaine-induced cardiac arrest extremely difficult.
Intralipid emulsion therapy (20%) should be immediately available whenever bupivacaine is used in significant doses. Refer to the LAST Protocol for emergency management.
IVRA Contraindication (Bier Block)
CONTRAINDICATED for IVRA (Bier block).
Bupivacaine must never be used for intravenous regional anesthesia. Tourniquet release delivers a bolus of bupivacaine directly into the systemic circulation, risking fatal cardiac arrest. This contraindication is absolute regardless of dose or tourniquet time. Use lidocaine for IVRA instead.
Levobupivacaine is the S-enantiomer of bupivacaine with similar anesthetic potency but reduced cardiotoxicity and CNS toxicity. It has a higher CC:CNS ratio, providing a greater margin of safety. Levobupivacaine is particularly preferred in neonatal and pediatric populations where CYP3A4 immaturity increases bupivacaine toxicity risk, and in high-volume blocks where systemic absorption is a concern.
Clinical Notes
Always calculate fractional toxicity when combining bupivacaine with other local anesthetics — toxicity is additive across agents.
Neonates (<1 month) have reduced alpha-1 acid glycoprotein levels, increasing the free (unbound) fraction of bupivacaine and elevating toxicity risk.
CYP3A4 does not reach adult activity until 9–12 months — dose reductions are essential in infants.
Epinephrine co-administration slows vascular absorption but does not reduce intrinsic cardiotoxicity. It provides some margin for peak plasma level reduction.
The 0.75% concentration is restricted to spinal use in many institutions due to reports of cardiac arrest with peripheral nerve block volumes at this concentration.
For neonatal regional anesthesia, chloroprocaine (ester metabolism) or levobupivacaine are preferred over racemic bupivacaine.
Have 20% intralipid emulsion immediately accessible. Know the LAST protocol.
Calculate Bupivacaine Doses Instantly
MaxLocal auto-calculates weight-based doses for bupivacaine and all common local anesthetics with pediatric age-based tiers, fractional toxicity tracking, and LAST protocol reference — all offline.
Berde CB, Strichartz GR. Local anesthetics. In: Miller's Anesthesia. 9th ed. Elsevier; 2020.
Suresh S, Ecoffey C, Bosenberg A, et al. The European Society of Regional Anaesthesia and Pain Therapy/American Society of Regional Anesthesia and Pain Medicine recommendations on local anesthetics and adjuvants dosage in pediatric regional anesthesia. Reg Anesth Pain Med. 2018;43(2):211-216.
Neal JM, Barrington MJ, Fettiplace MR, et al. The Third American Society of Regional Anesthesia and Pain Medicine Practice Advisory on Local Anesthetic Systemic Toxicity. Reg Anesth Pain Med. 2018;43(2):113-123.
Mazoit JX, Dalens BJ. Pharmacokinetics of local anaesthetics in infants and children. Clin Pharmacokinet. 2004;43(1):17-32.
Mather LE, Chang DH. Cardiotoxicity with modern local anaesthetics: is there a safer choice? Drugs. 2001;61(3):333-342.